Company intelligence / Profile preview

Cronos Group

Toronto, Ontario, Canadathecronosgroup.gcs-web.com ↗

Ownership: Public · CRON
Employees: ~459
Development stage: Commercial

Overview

Cronos Group is a leading global cannabinoid company focused on cannabis research, technology development, and commercialization. The company has achieved strong market positions in Canada and Israel with brands like Spinach® and PEACE NATURALS®, expanded into Germany and the UK through strategic partnerships, and continues to invest in R&D for next-generation cannabinoid products. In 2024 it reported $117.6 million in revenue (+35% YoY), driven by both recreational/adult-use sales in Canada and medical cannabis sales internationally[6][8].

Therapeutic areas: OtherPsychiatry
Modalities: Small moleculePlant-derived products
Industry: Non-Drug Biotech

Partnerships

Ginkgo Bioworks – biosynthetic cannabinoid R&D partnershipCansativa – distribution partner in GermanyGROW Pharma – distribution partner in UKVitura – distribution partner in Australia

Beyond the preview

Go deeper on Cronos Group.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cronos Group.

Explore the full profile